Navigation Links
Psyadon Announces Positive Interim Analysis of Phase 2 Study of Ecopipam for the Treatment of Tourette Syndrome
Date:7/24/2012

GERMANTOWN, Md., July 24, 2012 /PRNewswire/ -- Psyadon Pharmaceuticals, Inc. announced today that its Phase 2 study of ecopipam in patients with Tourette Syndrome was stopped early when a planned interim analysis revealed a statistically significant reduction in the severity of the patients' tic symptoms. This decision was supported by both the independent Drug Safety and Monitoring Committee overseeing the study and by the external Research Committee established as part of Psyadon's partnership with the Tourette Syndrome Association (TSA) - the nation's largest patient advocacy group for this disorder.

"Stopping this study early because of positive results is an important development for Psyadon and hopefully for patients with Tourette Syndrome," said Richard Chipkin, Ph.D., president and chief executive officer of Psyadon. "We are eager to move ecopipam into the next stages of clinical development."

Donald Gilbert, M.D., the study's principal investigator and professor and director of the Movement Disorder and Tourette Syndrome clinics at Cincinnati Children's Hospital Medical Center said "I am encouraged by the results of this study. I believe a lot of families are looking for new treatment options and current therapies have serious side effects. Although more investigation is needed, ecopipam may represent a safer, more effective choice."

Kevin McNaught, Ph.D., vice president for medical and scientific programs at the TSA added "The TSA is proud to have helped fund this study. There haven't been any new treatments for Tourette Syndrome approved by the FDA in over twenty years. Should ecopipam's efficacy be confirmed in future trials, it would be a welcome addition to the resources available to these patients."

About the Study

This Phase 2 study called 'Ecopipam Treatment of Tourette's Syndrome (PSY301)', was a multicenter, open-label, nonrandomized study conducted to assess the ac
'/>"/>

SOURCE Psyadon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Egalet Announces Issuance of U.S. Patent
2. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
3. Sancilio and Company Announces New Directors
4. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
5. K-V Pharmaceutical Company Announces Additional Notification from NYSE Regarding Listing Criteria
6. Kraton Performance Polymers, Inc. Announces Second Quarter 2012 Earnings Release Conference Call and Webcast and 2012 Investor Day and Webcast
7. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
8. Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe
9. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. China Health Resource Announces Go Global Initiative For New Product Introductions
11. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... 15, 2014 The Cadence Fitness & Health Center ... the Medical Fitness Association, a non-profit organization assisting medically ... potential. The Cadence Fitness & Health Center is the ... second in the Chicagoland area. "The certification ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... April 20 Scientists from the Barbara ... presented data at the American Association for ... represents significant research advancements in the treatment ... breast cancer.(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO )Karmanos researchers discovered ...
... Improves Survival in Animals with Clinical Symptoms of ... 20 Elusys Therapeutics, Inc. (Elusys), ... the treatment of life-threatening infectious diseases, today announced ... safety trial of Anthim(TM), a high-affinity humanized ...
Cached Medicine Technology:Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference 2Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference 3Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study 2Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study 3
(Date:4/23/2014)... wealthy as the United States, it may come as a ... to adequate food due to lack of money or other ... at the University of Illinois using data from the National ... who are dealing with hunger are also facing negative health ... Americans over age 60 faced the threat of hungerthat translates ...
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where different ... signatures within the same cancer. Such differences could ... strategies. , Firstly they confirmed the mutual exclusivity ... or BRAF mutation. Secondly, they found that lung ... that specific mutation present uniformly throughout the tumour, ...
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... 15 percent of all lung cancers are small ... often develop resistance to chemotherapy. However, researchers at ... new insights into the mechanisms leading to this ... , Chemotherapies work primarily by mediating B-cell lymphoma ... regulating cell death. Depending on their function, this ...
(Date:4/22/2014)... is the standard measurement for assessing glycemic control over ... are typically measured every few months in a laboratory, ... accurately estimates A1c using self-monitored blood glucose (SMBG) readings, ... ( DTT ), a peer-reviewed journal from Mary Ann ... the DTT website at http://www.liebertpub.com/dtt . ...
Breaking Medicine News(10 mins):Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2
... "Occlusions in the retinal vein could not only make you loose ... veins is so painful that the eye may have to be ... new instrument that uses a plasma to shoot tiny bullets ... vessels that supply blood to the retina drain into a single ...
... market is currently dominated by the Mumbai based ... company, is planning to enter the anti-AIDS drugs ... and west Asia, S D Kaul, the company ... Aabacavir and Indinavir products in the Indian market ...
... that can have Complication as its other name. Among the ... be the foot ulcer, as damage can be severe enough ... ulcer, a boon in disguise would be a new device ... //Such an electrical stimulation would help in the healing of ...
... procedure widely used on knees can also repair damaged ... best known for repairing knee injuries, but it is ... it is a minimally invasive surgical technique it is ... relieve different ankle problems, including ligament damage, bone chips ...
... basis. One of these latest laser techniques is helpful in ... This degenerative condition cause blood vessels to grow underneath the ... ,Eye specialists have come up with a new therapy ... of damaging the retinal tissue. ,This is a two-step ...
... active ingredient is Acetaminophen is found effective in the ... temperature in people who have had a stroke, according ... ,Rise in the body temperature during the first few ... fever, has been linked to poorer outcomes including an ...
Cached Medicine News:Health News:Blocked viens block eye sight 2Health News:Arthroscopy for Ankles 2
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: